Lymph node macrophage-targeted interferon alpha boosts anticancer immune responses by regulating CD169-positive phenotype of macrophages.

Authors: Fukuda, Ryo¹ (AUTHOR), Fujiwara, Yukio² (AUTHOR), Maeda, Hitoshi^1,3 (AUTHOR), Pan, Cheng² (AUTHOR), Minayoshi, Yuki¹ (AUTHOR), Yano, Hiromu^2,4 (AUTHOR), Mizuta, Yuki¹ (AUTHOR), Takano, Mei¹ (AUTHOR), Yamada, Rin² (AUTHOR), Saito, Yoichi⁵ (AUTHOR), Hirata, Kenshiro⁶ (AUTHOR), Imoto, Shuhei⁶ (AUTHOR), Yamasaki, Keishi⁶ (AUTHOR), Oniki, Kentaro⁷ (AUTHOR), Saruwatari, Junji⁷ (AUTHOR), Otagiri, Masaki⁶ (AUTHOR), Watanabe, Hiroshi¹ (AUTHOR) hnabe@kumamoto-u.ac.jp, Komohara, Yoshihiro² (AUTHOR) ycomo@kumamoto-u.ac.jp, Maruyama, Toru¹ (AUTHOR) tomaru@gpo.kumamoto-u.ac.jp

Source: Molecular Cancer. 5/3/2025, Vol. 24 Issue 1, p1-19. 19p.

Subject Terms: *CYTOTOXIC T cells, *PROGRAMMED death-ligand 1, *IMMUNE checkpoint inhibitors, *MEDICAL sciences, *ANTIGEN presentation

PD-1 regulates the anti-tumor immune function of macrophages through JAK2-STAT3 signaling pathway in colorectal cancer tumor microenvironment.

Authors: Jiang, Han^1,2 (AUTHOR), Pang, Jingjing¹ (AUTHOR), Li, Tengyue² (AUTHOR), Akofala, Atitso¹ (AUTHOR), Zhou, Xiaoxi³ (AUTHOR), Yi, Changhua⁴ (AUTHOR), Ning, Shangwei² (AUTHOR) ningsw@ems.hrbmu.edu.cn, Gao, Xu^1,5 (AUTHOR) gaoxu6712@163.com, Qiao, Yu¹ (AUTHOR) qiaoyuhmu@163.com, Kou, Jiayuan¹ (AUTHOR) jiayuankou1992@outlook.com

Source: Journal of Translational Medicine. 5/2/2025, Vol. 23 Issue 1, p1-17. 17p.

Subject Terms: *PROGRAMMED death-ligand 1, *IMMUNE checkpoint proteins, *MEDICAL sciences, *GENE expression, *RNA sequencing

Combination of epirubicin and cyclophosphamide for the treatment of advanced pulmonary sarcomatoid carcinoma: A case report and literature review.

Authors: Deng, Ruoyu¹ (AUTHOR), Lv, Jialing¹ (AUTHOR), Wang, Fang² (AUTHOR), Chen, Yanqiong¹ (AUTHOR), Wang, Junfeng¹ (AUTHOR), Wang, Lin¹ (AUTHOR), Mu, Lixia¹ (AUTHOR), Zhang, Zhijun¹ (AUTHOR), Zhang, Wen¹ (AUTHOR) zhangwen@kmmu.edu.cn, Zhang, Chao¹ (AUTHOR) zhangchao@kmmu.edu.cn

Source: Journal of Cancer Research & Therapeutics. May2025, Vol. 21 Issue 2, p512-517. 6p.

Subject Terms: *PROGRAMMED death-ligand 1, *NON-small-cell lung carcinoma, *COMBINATION drug therapy, *PROGRESSION-free survival, *GENETIC mutation

Neutrophil-to-lymphocyte ratio-based prognostic score can predict outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy plus chemotherapy.

Authors: Liao, Shan¹ (AUTHOR), Sun, Huiying¹ (AUTHOR), Lu, Hao¹ (AUTHOR), Wu, Jiani¹ (AUTHOR), Wu, Jianhua¹ (AUTHOR), Wu, Zhe¹ (AUTHOR), Xi, Jingle¹ (AUTHOR), Liao, Wangjun^1,2 (AUTHOR) nfyyliaowj@163.com, Wang, Yuanyuan¹ (AUTHOR) doc_wang@126.com

Source: BMC Cancer. 4/15/2025, Vol. 25 Issue 1, p1-15. 15p.

Subject Terms: *PROGRAMMED death-ligand 1, *NEUTROPHIL lymphocyte ratio, *EPIDERMAL growth factor receptors, *NON-small-cell lung carcinoma, *PLATELET lymphocyte ratio

Predicting PD-L1 status in NSCLC patients using deep learning radiomics based on CT images.

Authors: Lu, Jiameng^1,2 (AUTHOR), Liu, Xinyi¹ (AUTHOR), Ji, Xiaoqing³ (AUTHOR), Jiang, Yunxiu¹ (AUTHOR), Zuo, Anli¹ (AUTHOR), Guo, Zihan¹ (AUTHOR), Yang, Shuran¹ (AUTHOR), Peng, Haiying⁴ (AUTHOR), Sun, Fei⁵ (AUTHOR), Lu, Degan¹ (AUTHOR) deganlu@126.com

Source: Scientific Reports. 4/11/2025, Vol. 15 Issue 1, p1-12. 12p.

Subject Terms: *PROGRAMMED death-ligand 1, *NON-small-cell lung carcinoma, *MAGNETIC resonance imaging, *COMPUTED tomography, *FEATURE extraction

Immunoinformatics based designing of a multi-epitope cancer vaccine targeting programmed cell death ligand 1.

Authors: Mahafujul Alam, Syed Sahajada¹ (AUTHOR), Mir, Showkat Ahmad² (AUTHOR), Samanta, Arijit¹ (AUTHOR), Nayak, Binata² (AUTHOR), Ali, Safdar³ (AUTHOR), Hoque, Mehboob^1,4 (AUTHOR) m_hoque@aliah.ac.in

Source: Scientific Reports. 4/11/2025, Vol. 15 Issue 1, p1-26. 26p.

Subject Terms: *PROGRAMMED death-ligand 1, *IMMUNE checkpoint proteins, *IMMUNE checkpoint inhibitors, *MEDICAL sciences, *RIBOSOMAL proteins

Downregulation of PD-L1 expression by Wnt pathway inhibition to enhance PD-1 blockade efficacy in hepatocellular carcinoma.

Authors: Shao, Yu-Yun^1,2,3 (AUTHOR), Wang, Han-Yu² (AUTHOR), Hsu, Hung-Wei² (AUTHOR), Wo, Rita Robin² (AUTHOR), Cheng, Ann-Lii^1,2,3,4 (AUTHOR), Hsu, Chih-Hung^1,2,3 (AUTHOR) chihhunghsu@ntu.edu.tw

Source: Biology Direct. 4/10/2025, Vol. 20 Issue 1, p1-12. 12p.

Subject Terms: *PROGRAMMED death-ligand 1, *WNT signal transduction, *PROTEOLYSIS, *HEPATOCELLULAR carcinoma, *GENETIC translation

Long-Term Outcomes in Patients with Locally Advanced and Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression.

Authors: Ćeriman Krstić, Vesna^1,2 (AUTHOR) ceriman.vesna@gmail.com, Soldatović, Ivan^2,3 (AUTHOR), Gajić, Milija^2,3 (AUTHOR), Samardžić, Natalija^2,4 (AUTHOR), Stević, Ruža^1,4,5 (AUTHOR), Čolić, Nikola^1,4,6 (AUTHOR), Lukić, Katarina^4,7 (AUTHOR), Šeha, Biljana^5,8 (AUTHOR), Radončić, Damir² (AUTHOR), Stamenić, Slavko² (AUTHOR), Savić, Milan^1,6 (AUTHOR), Milenković, Vladimir^1,6 (AUTHOR), Milošević Maračić, Brankica⁷ (AUTHOR), Jovanović, Dragana⁸ (AUTHOR)

Source: Current Oncology. Apr2025, Vol. 32 Issue 4, p229. 9p.

Subject Terms: *PROGRAMMED death-ligand 1, *PEMBROLIZUMAB, *IMMUNOTHERAPY, *PROGRESSION-free survival, *NON-small-cell lung carcinoma, *OVERALL survival, *FIELD research, *TREATMENT effectiveness

Expression and clinical significance of programmed cell death protein 1/programmed death-ligand 1 in non-small cell lung cancer patients with rare mutations of epidermal growth factor receptor gene: A retrospective cohort study.

Authors: Du, Yuan¹ (AUTHOR) staff1239@yxph.com, Zhuang, Zeliang¹ (AUTHOR), Zong, Lijun¹ (AUTHOR), Xu, Yongxing¹ (AUTHOR)

Source: CytoJournal. 4/1/2025, Vol. 22, p1-10. 10p.

Subject Terms: *PROGRAMMED death-ligand 1, *RETROSPECTIVE studies, *DESCRIPTIVE statistics, *GENE expression, *LONGITUDINAL method, *IMMUNOHISTOCHEMISTRY, *LUNG cancer, *GENETIC mutation, *CANCER genes, *PROGRESSION-free survival, *IMMUNE checkpoint proteins, *EPIDERMAL growth factor receptors, *OVERALL survival

PD-L1-Targeting Nanoparticles for the Treatment of Triple-Negative Breast Cancer: A Preclinical Model.

Authors: Nevala, Wendy K.¹ (AUTHOR), Geng, Liyi^1,2 (AUTHOR), Xie, Hui^1,2 (AUTHOR), Stueven, Noah A.^1,2 (AUTHOR), Markovic, Svetomir N.¹ (AUTHOR) markovic.svetomir@mayo.edu

Source: International Journal of Molecular Sciences. Apr2025, Vol. 26 Issue 7, p3295. 18p.

Subject Terms: *PROGRAMMED death-ligand 1, *TRIPLE-negative breast cancer, *CANCER chemotherapy, *NON-Hodgkin's lymphoma, *UTERINE cancer

Clinicopathological characteristics and the relationship of PD-L1 status, tumor mutation burden, and microsatellite instability in patients with esophageal carcinoma.

Authors: Li, Suyao¹ (AUTHOR), Yu, Yongling¹ (AUTHOR), Xu, Yirong² (AUTHOR), Zhou, Yue³ (AUTHOR), Huang, Junxing⁴ (AUTHOR) obli46@163.com, Jia, Jinghao¹ (AUTHOR) r3ku33@163.com

Source: BMC Cancer. 3/31/2025, Vol. 25 Issue 1, p1-9. 9p.

Subject Terms: *PROGRAMMED death-ligand 1, *IMMUNOSTAINING, *MEDICAL sciences, *IMMUNE checkpoint inhibitors, *IMMUNOHISTOCHEMISTRY

Blocking copper transporter protein-dependent drug efflux with albumin-encapsulated Pt(IV) for synergistically enhanced chemo-immunotherapy.

Authors: Fang, Man^1,2 (AUTHOR), Cao, Lei^2,3,4,5 (AUTHOR), Zhang, Zhao⁶ (AUTHOR), Yu, Zhen^1,2 (AUTHOR), Shen, Yue^1,2 (AUTHOR), Chen, Jieqi^1,2 (AUTHOR), Chen, Juan^1,2 (AUTHOR), Li, Yue-Qin² (AUTHOR), Liu, Zhaoqian^2,3,4 (AUTHOR), Meng, Yingcai^1,2 (AUTHOR), Xiao, Haihua⁷ (AUTHOR), Qu, Qiang^1,2 (AUTHOR) quqiang@csu.edu.cn, Yin, Ji-Ye^2,3,4,5 (AUTHOR) yinjiye@csu.edu.cn, Li, Xiang-Ping^1,2 (AUTHOR) xylxping@csu.edu.cn

Source: Journal of Nanobiotechnology. 3/18/2025, Vol. 23 Issue 1, p1-20. 20p.

Subject Terms: *PROGRAMMED death-ligand 1, *NON-small-cell lung carcinoma, *PLATINUM compounds, *COPPER, *LUNG cancer

Impacts of combining PD-L1 inhibitor and radiotherapy on the tumour immune microenvironment in a mouse model of esophageal squamous cell carcinoma.

Authors: Yin, Zihao¹ (AUTHOR) yinzihao184927@163.com, Zhang, Hongfang² (AUTHOR) zhanghongfang8633@163.com, Zhang, Ke¹ (AUTHOR) zhangke2003511@163.com, Yue, Jing² (AUTHOR) yj17ying@163.com, Tang, Rongjun³ (AUTHOR) tangrongjun1@163.com, Wang, Yaping⁴ (AUTHOR) 157179609@qq.com, Deng, Qinghua¹ (AUTHOR) dengqinghua69@163.com, Yu, Qingqing¹ (AUTHOR) yuqq1983@163.com

Source: BMC Cancer. 3/14/2025, Vol. 25 Issue 1, p1-15. 15p.

Subject Terms: *PROGRAMMED death-ligand 1, *REGULATORY T cells, *MYELOID-derived suppressor cells, *MEDICAL sciences, *IMMUNOLOGIC memory

Link of TMPRSS2 expression with tumor immunogenicity and response to immune checkpoint inhibitors in cancers.

Authors: Subbarayan, Karthikeyan¹ (AUTHOR), Bieber, Helena¹ (AUTHOR), Massa, Chiara² (AUTHOR), Rodríguez, Felipe Adonis Escalona^1,3,4 (AUTHOR), Hossain, SM Al Amin¹ (AUTHOR), Neuder, Lisa¹ (AUTHOR), Wahbi, Wafa⁵ (AUTHOR), Salo, Tuula^5,6 (AUTHOR), Tretbar, Sandy⁷ (AUTHOR), Al-Samadi, Ahmed^5,8 (AUTHOR), Seliger, Barbara^1,2,7 (AUTHOR) barbara.seliger@uk-halle.de

Source: Journal of Translational Medicine. 3/7/2025, Vol. 23 Issue 1, p1-16. 16p.

Subject Terms: *PROGRAMMED death-ligand 1, *HISTOCOMPATIBILITY class I antigens, *MONONUCLEAR leukocytes, *MEDICAL sciences, *IMMUNE checkpoint inhibitors, *HLA-B27 antigen

Current Biomarkers in Non-Small Cell Lung Cancer—The Molecular Pathologist's Perspective.

Authors: Steinestel, Konrad¹ (AUTHOR) konradsteinestel@bundeswehr.org, Arndt, Annette¹ (AUTHOR)

Source: Diagnostics (2075-4418). Mar2025, Vol. 15 Issue 5, p631. 16p.

Subject Terms: *PROGRAMMED death-ligand 1, *NON-small-cell lung carcinoma, *MOLECULAR pathology, *CANCER-related mortality, *NUCLEOTIDE sequencing

Advances and challenges in gastric cancer testing: the role of biomarkers.

Authors: Yu Sun¹, Puspanathan, Pavitratha², Lim, Tony³, Dongmei Lin⁴ lindm3@163.com

Source: Cancer Biology & Medicine. Mar2025, Vol. 22 Issue 3, p212-230. 19p.

Subject Terms: *EPIDERMAL growth factor receptors, *PROGRAMMED death-ligand 1, *IMMUNE checkpoint inhibitors, *CANCER patients, *TUMOR markers

Study on Cantharidin Reversing the Drug-resistance of Non-small Cell Lung Cancer to DDP by Regulating the Expression of PD-L1.

Authors: Jin, Xing¹ (AUTHOR), Ma, Chunhui² (AUTHOR), Tan, Xiaojing³ (AUTHOR), Qian, Jian¹ (AUTHOR), Chen, Yongbing¹ (AUTHOR) 768365879@qq.com, Wang, Dongfeng⁴ (AUTHOR) dongfengwang3620@sohu.com

Source: Pharmacognosy Magazine. Mar2025, Vol. 21 Issue 1, p74-80. 7p.

Subject Terms: *PROGRAMMED death-ligand 1, *NON-small-cell lung carcinoma, *DRUG resistance, *CISPLATIN, *CELL lines

Advances in Melanoma and Skin Cancers.

Authors: Mallardo, Domenico¹ (AUTHOR) d.mallardo@istitutotumori.na.it, Basile, Debora² (AUTHOR), Vitale, Maria Grazia¹ (AUTHOR)

Source: International Journal of Molecular Sciences. Mar2025, Vol. 26 Issue 5, p1849. 4p.

Subject Terms: *PROGRAMMED death-ligand 1, *TREATMENT effectiveness, *IMMUNE checkpoint inhibitors, *VASCULOGENIC mimicry, *PROGNOSIS, *BRAF genes

A Comparative Molecular Dynamics Study of Food-Derived Compounds as PD-L1 Inhibitors: Insights Across Six Flavonoid Subgroups.

Authors: Jiang, Dejun¹ (AUTHOR), Kwon, Hyuk-Ku^1,2 (AUTHOR), Kwon, Oh Wook^2,3 (AUTHOR), Choi, Youngjin^1,3 (AUTHOR) ojchoi@hoseo.edu

Source: Molecules. Feb2025, Vol. 30 Issue 4, p907. 21p.

Subject Terms: *PROGRAMMED death-ligand 1, *MOLECULAR dynamics, *ROOT-mean-squares, *MOLECULAR interactions, *FLAVONOIDS, *HESPERIDIN

A Critical Role of Intracellular PD-L1 in Promoting Ovarian Cancer Progression.

Authors: Huang, Rui¹ (AUTHOR) ruhuang@coh.org, Nakamura, Brad² (AUTHOR) bnakamura@coh.org, Senguttuvan, Rosemary² (AUTHOR) rsenguttuvan@coh.org, Li, Yi-Jia¹ (AUTHOR) yili@coh.org, Martincuks, Antons¹ (AUTHOR) amartincuks@coh.org, Bakkar, Rania³ (AUTHOR) rbakkar@coh.org, Song, Mihae² (AUTHOR) misong@coh.org, Ann, David K.⁴ (AUTHOR) dann@coh.org, Rodriguez-Rodriguez, Lorna² (AUTHOR) lorrodriguez@coh.org, Yu, Hua¹ (AUTHOR) hyu@coh.org

Source: Cells (2073-4409). Feb2025, Vol. 14 Issue 4, p314. 19p.

Subject Terms: *PROGRAMMED cell death 1 receptors, *PROGRAMMED death-ligand 1, *OVARIAN cancer, *CANCER invasiveness, *CELL cycle